Boston – April 28, 2026 – Cooley advised the underwriters of Oruka Therapeutics (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, on Oruka’s upsized underwritten public offering of 9,660,000 shares of its common stock at a public offering price of $72.50 per share. In addition, Oruka has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,449,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Leerink Partners, TD Cowen, Goldman Sachs & Co., Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as passive bookrunning manager for the offering.

Partners Eric Blanchard, Daniel Goldberg, Minkyu Park led the Cooley team advising the underwriters with support from Phil Mitchell, Madhuri Roy and Randy Sabett.

Cooley has represented the banks on all of Oruka’s capital raising transactions since it spun out from Paragon Therapeutics in 2024 and went public through a reverse merger with Arca biopharma, including as counsel to the placement agents on three private investments in public equity and to the sales agent on its at-the-market offering program.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.